Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer novel PET tracer to be adopted by AC Immune SA

Bayer novel PET tracer to be adopted by AC Immune SA

8th October 2009

Bayer’s novel PET (positron emission tomography) tracer florbetaben is to be adopted by biopharmaceutical company AC Immune SA to support a clinical trial in the field of Alzheimer’s disease (AD), it has been announced.

The trial aims to discover a therapy option for the treatment of AD and florbetaben will be applied for imaging of beta-Amyloid deposition in the brain of patients undergoing the clinical testing of AC Immune’s Alzheimer’s vaccine ACI-24.

This marks the first time florbetaben has been tested for the development of a potential therapeutic for Alzheimer’s patients.

Dr Thomas Balzer, head of global clinical development therapeutic area diagnostic imaging at Bayer, said: “The cooperation with AC Immune enables the collection of valuable clinical data for florbetaben in patients treated with AC Immune’s novel therapeutic vaccine.”

Bayer this week presented the positive results of a trial into its oral contraceptive Qlaira, which is designed to ease menstrual blood loss in women suffering from heavy or prolonged menstrual bleeding.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.